Denali Therapeutics Inc. (DNLI)
$22.31
$-0.49
(-2.15%)
As on 04-Sep-2026 13:35EDT
Market cap
$3,836 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
4.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
86.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.8
-
Face value
--
-
Shares outstanding
159,847,403
9 Years Aggregate
CFO
$-663.45 Mln
EBITDA
$-1,159.97 Mln
Net Profit
$-1,116.14 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
| 35.1 | -3.6 | 13.5 | 45.7 | -1.5 | -16.4 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
| -19.0 | -5.0 | -22.8 | -37.6 | -46.8 | 380.8 | -15.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Denali Therapeutics (DNLI)
|
22.3 | 3,836.3 | 3.6 | -511.5 | -14,188.4 | -55.3 | -- | 4.7 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout Denali Therapeutics (DNLI)
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral... inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Read more
-
Co-Founder, President, CEO & Director
Dr. Ryan J. Watts Ph.D.
-
Co-Founder, President, CEO & Director
Dr. Ryan J. Watts Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Denali Therapeutics (DNLI)
What is the current share price of Denali Therapeutics Inc (DNLI) Today?
The share price of Denali Therapeutics Inc (DNLI) is $22.31 (NASDAQ) as of 04-Sep-2026 13:35 EDT. Denali Therapeutics Inc (DNLI) has given a return of -1.45% in the last 3 years.
What is the current PB & PE ratio of Denali Therapeutics Inc (DNLI)?
Since, TTM earnings of Denali Therapeutics Inc (DNLI) is negative, P/E ratio is not available.
The P/B ratio of Denali Therapeutics Inc (DNLI) is 4.72 times as on 28-Aug-2026, a 9 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.65 |
2.86 |
2024 |
-8.20 |
2.82 |
2023 |
-20.43 |
2.88 |
2022 |
-11.34 |
3.54 |
2021 |
-18.75 |
5.66 |
What is the 52 Week High and Low of Denali Therapeutics Inc (DNLI)?
The 52-week high and low of Denali Therapeutics Inc (DNLI) are Rs 27.30 and Rs 12.58 as of 05-Sep-2026.
What is the market cap of Denali Therapeutics Inc (DNLI)?
Denali Therapeutics Inc (DNLI) has a market capitalisation of $ 3,836 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Denali Therapeutics Inc (DNLI)?
Before investing in Denali Therapeutics Inc (DNLI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.